Home / Solutions / Medical weight loss
For GLP-1 & medical weight-loss programs30 million Americans are on GLP-1s, and the market is shifting from pill-mill scripts to clinically-guided programs. CareOS is the platform for the clinics doing it right: titration protocols with built-in monitoring, patient check-ins between visits (nausea, adherence, energy) with AI change summaries and red-flag triage, weight and InBody trends on one chart, and every transmitted script booking its own day-14 follow-up.
What software do GLP-1 clinics use? The clinics that outlast the gold rush run structured titration protocols with safety holds, automated weekly check-ins, lab checkpoints, and program-based billing — plus multi-state compliance if they prescribe via telehealth. CareOS makes that whole loop one system.
Semaglutide and tirzepatide templates with dose steps and hold conditions — grade-2 GI events, insufficient response, overdue labs — enforced automatically.
Weight, GI symptoms, and adherence collected through the portal on schedule. Non-responders and side-effect flags surface to your queue, not your inbox.
CMP, A1c, and lipid draws scheduled by the protocol. Results land on the protocol timeline and unblock (or hold) the next dose step.
Body composition, resistance-training programs, protein targets, and coaching enrollment — the muscle-preserving program design that separates clinics from script mills.
Monthly program memberships with meds, labs, and coaching bundled. Deposits, cards on file, pause/resume for supply interruptions.
Telehealth GLP-1 across state lines with real-time license gating. Expansion never outruns eligibility.
"When the compounding window closed, the clinics with real programs kept their patients. The ones selling vials didn't. This platform is how you build the first kind."Founder, metabolic health program (CareOS design partner)
Regulatory status of compounded GLP-1s is under active FDA review — last reviewed Aug 10, 2026. FDA has proposed, not finalized, excluding semaglutide and tirzepatide from the 503B bulks list (91 FR 23431, May 1, 2026; comments closed Jul 30, 2026); bulk compounding otherwise remains tied to FDA drug-shortage status. Verify current status with the FDA before making program decisions.
Setup walkthrough · Growth $189/provider/mo · Migration path included · Founding practices get 20% off for life